DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06023095

CompletedPhase 1

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

A Multiple Dose Titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Chinese Participants Who Have Obesity or Are Overweight With Weight-related Comorbidities

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

3

Recruiting sites

—

Enrollment

24

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06023095
Org study ID18610
Secondary IDJ2A-GH-GZGXEli Lilly and Company

Timeline

Milestones

Study first posted2023-09-05actual
Study start2023-09-21actual
Primary completion2024-07-29actual
Study completion2024-07-29actual
Last update posted2024-08-27actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Are native Chinese males or females
•Have had a stable body weight for the 3 months prior to randomization (less than 5% body weight change) and body mass index of ≥ 30.0 kilograms per square meter (kg/m²) or between 27.0 up to 30.0 kg/m² with at least 1 of the following weight-related comorbidities including Hypertension, Dyslipidemia, Cardiovascular disease, Obstructive sleep apnea

Exclusion criteria

•Have any prior diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus
•Have used or intend to use any prescription or over-the-counter medications or traditional Chinese treatments within 3 months prior to screening, exception of medications for the treatment of concurrent medical conditions with a stable dose
•Have known allergies to GLP-1RAs, LY3502970, related compounds, any components of the formulation, or have a history of significant atopy
•Are overweight or have obesity induced by other endocrinological disorders, diagnosed monogenetic, or syndromic forms of obesity
•Have or plan to have a surgical, endoscopic or device-based treatment for obesity
•Have a history or presence of psychiatric disorder, a moderately severe or severe depression status, or a significantly risk for suicide
•Have a history of acute or chronic pancreatitis
•Have a known self or family history of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma
•Have other acute, chronic, or uncontrolled medical conditions, vital organ failure or abnormal laboratory value in the judgment of the investigator would make the participant inappropriate for entry into this study

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Safety / tolerability / PK
3
Glycemic / diabetes
1

Weight & body composition

3 endpoints
Secondary/protocol endpoint

Pharmacodynamics (PD): Change From Baseline in Body Weight

Time frame:Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

PD: Change From Baseline in Body Mass Index

Time frame:Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

PD: Change From Baseline in Waist Circumference

Time frame:Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

PD: Change From Baseline in Fasting Plasma Glucose

Time frame:Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

3 endpoints
Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Time frame:Predose on Day 1 up to 116 (Cohort 1) & 172 (Cohort 2) Days postdose

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 hour Time Point (AUC0-24) of LY3502970

Time frame:Predose on Day 1 up to 116 (Cohort 1) & 172 (Cohort 2) Days postdose

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.